Fusion Protein for the Treatment of Immunologic or Allergic Reactions

Simple SummaryContent extracted from patent full text and abstract with AI.

This invention describes a fusion protein (such as Ontak) comprising a truncated bacterial toxin domain (e.g., diphtheria toxin) fused to a mammalian cell-targeting domain (e.g., human interleukin-2). The primary use of this fusion protein is to induce a tolerogenic state in dendritic cells (DCs), making them suppress immune responses rather than stimulate them. This tolerization has applications in reducing undesirable immune or allergic reactions by reprogramming the immune system to tolerate specific antigens. The approach can be used as a medication, in cell therapy ex vivo, and potentially as part of new vaccination or transplantation tolerance strategies.

Use CasesContent extracted from patent full text and abstract with AI.

• Preventing organ transplant rejection by inducing immune tolerance in recipients to the transplanted tissue or organ.
• Treating autoimmune diseases such as multiple sclerosis, type 1 diabetes, or rheumatoid arthritis by reducing detrimental immune responses against self-tissues.
• Desensitizing patients to specific allergens, providing an alternative to conventional allergy immunotherapy for conditions like pollen or food allergies.
• Developing tolerogenic vaccines for targeted immune tolerance (e.g., for protein replacement therapies or gene therapy vectors).
• Preparing tolerogenic dendritic cells or regulatory T cells ex vivo for adoptive cellular therapies in immune-mediated diseases.
• Reducing graft-versus-host disease (GVHD) in hematopoietic stem cell or bone marrow transplants.

BenefitsContent extracted from patent full text and abstract with AI.

• Targets immune tolerance at the level of dendritic cells, providing a novel approach for controlling immune responses.
• Reduces the need for long-term systemic immunosuppression, minimizing the risks of infections and drug-related side effects.
• Enables antigen-specific tolerization, which can lead to more precise and effective therapies with fewer off-target effects.
• Can be tailored for both systemic and antigen-specific immune tolerance depending on clinical need.
• Facilitates generation of tolerogenic DCs and regulatory T cells ex vivo, supporting advanced cell-based therapies for immune disorders and transplantation.
• Potentially broadens indications to autoimmunity, transplantation, allergy, and novel vaccination strategies.

Technical Classifications (CPCs)

Inventors & Applicants

Patent Abstract

The present invention relates to the field of human medicine, namely the treatment of undesirable immunological or allergic reactions.